1. The lysosomal storage disorders mucolipidosis type II, type III alpha/beta, and type III gamma: Update on GNPTAB and GNPTG mutations
- Author
-
Barbara Tappino, Renata Voltolini Velho, Nicole Muschol, Karen Tylee, Mirella Filocamo, Kerstin Kutsche, Frederike L. Harms, Esmee Oussoren, Sara S Cathey, Christine Petersen, Ida Vanessa Doederlein Schwartz, Lesley Heptinstall, Beyhan Tüysüz, Michael J. Friez, Sandra Alves, Gloria Durán Saavedra, Sandra Pohl, Nilay Güneş, Tatyana Danyukova, Nataniel Floriano Ludwig, Ans T. van der Ploeg, Kathryn L. Brammeier, and Pediatrics
- Subjects
Lysosomal Storage Diseases, Nervous System ,Transferases (Other Substituted Phosphate Groups) ,Mannose 6-phosphate ,Biology ,medicine.disease_cause ,GNPTG ,03 medical and health sciences ,chemistry.chemical_compound ,Protein Domains ,Mucolipidoses ,Genetics ,medicine ,Humans ,Missense mutation ,Genetics (clinical) ,030304 developmental biology ,0303 health sciences ,Mutation ,Coarse facial features ,Mucolipidosis ,030305 genetics & heredity ,Exons ,Prognosis ,medicine.disease ,Phenotype ,Molecular biology ,Introns ,Doenças Genéticas ,chemistry - Abstract
Mutations in the GNPTAB and GNPTG genes cause mucolipidosis (ML) type II, type III alpha/beta, and type III gamma, which are autosomal recessively inherited lysosomal storage disorders. GNPTAB and GNPTG encode the α/β-precursor and the γ-subunit of N-acetylglucosamine (GlcNAc)-1-phosphotransferase, respectively, the key enzyme for the generation of mannose 6-phosphate targeting signals on lysosomal enzymes. Defective GlcNAc-1-phosphotransferase results in missorting of lysosomal enzymes and accumulation of non-degradable macromolecules in lysosomes, strongly impairing cellular function. MLII-affected patients have coarse facial features, cessation of statural growth and neuromotor development, severe skeletal abnormalities, organomegaly, and cardiorespiratory insufficiency leading to death in early childhood. MLIII alpha/beta and MLIII gamma are attenuated forms of the disease. Since the identification of the GNPTAB and GNPTG genes, 564 individuals affected by MLII or MLIII have been described in the literature. In this report, we provide an overview on 258 and 50 mutations in GNPTAB and GNPTG, respectively, including 58 novel GNPTAB and seven novel GNPTG variants. Comprehensive functional studies of GNPTAB missense mutations did not only gain insights into the composition and function of the GlcNAc-1-phosphotransferase, but also helped to define genotype-phenotype correlations to predict the clinical outcome in patients. Brazilian National Council for Scientific and Technological Development/International; 125440785-SFB877/Deutsche Forschungsgemeinschaft/International; PO 1539/1-1/Deutsche Forschungsgemeinschaft/International; 395238399-PO 1539/1-1/Deutsche Forschungsgemeinschaft/International; KU 1240/10-1/Deutsche Forschungsgemeinschaft/International; Cinque per mille e Ricerca Corrente, Ministero della Salute/International. This study was funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, 125440785‐ SFB877, 395238399‐PO 1539/1‐1 to S. P. and 1240/10‐1 to K. K.), the Brazilian National Council for Scientific and Technological Development (CNPq) to N. F. L. and by unrestricted grants from Cinque per mille e Ricerca Corrente, Ministero della Salute to M. F. and B. T. info:eu-repo/semantics/publishedVersion
- Published
- 2019
- Full Text
- View/download PDF